RICHARD C. MULLIGAN

Corporate Board Profile

Tech Score: 13/100

Software Technology Evidence

1 mention(s) identify RICHARD C. MULLIGAN as having software/technology expertise.

Company	Filing Date	Evidence	Reason
Bausch Health Companies Inc.	2022-05-02	Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. Dr. Mulligan also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, Inc. a public biotechnology company, and a director of Biogen Inc., a public biotechnology company. Prior to Harvard, Dr. Mulligan was a professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and chief scientific officer of Somatix Therapy Corporation, a drug discovery and development company that he founded.	Dr. Mulligan has extensive experience in biotechnology and academia, including roles as a professor of genetics and executive vice chairman of a biotechnology company, indicating strong technical and scientific expertise that likely includes programming or related skills.

Bausch Health Companies Inc.

Filing Date	Source Excerpt
2022-05-02	Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. Dr. Mulligan also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, Inc. a public biotechnology company, and a director of Biogen Inc., a public biotechnology company. Prior to Harvard, Dr. Mulligan was a professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and chief scientific officer of Somatix Therapy Corporation, a drug discovery and development company that he founded.
2023-04-06	Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. Dr. Mulligan also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, Inc. a public biotechnology company, and a director of Biogen Inc., a public biotechnology company. Prior to Harvard, Dr. Mulligan was a professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and chief scientific officer of Somatix Therapy Corporation, a drug discovery and development company that he founded.

Filing Date

Source Excerpt

2022-05-02

Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. Dr. Mulligan also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, Inc. a public biotechnology company, and a director of Biogen Inc., a public biotechnology company. Prior to Harvard, Dr. Mulligan was a professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and chief scientific officer of Somatix Therapy Corporation, a drug discovery and development company that he founded.

2023-04-06

BIOGEN INC.

Filing Date	Source Excerpt
2015-04-30	Dr. Mulligan has scientific expertise in the areas of molecular biology, genetics, gene therapy, and biotechnology, as well as extensive experience within the healthcare industry, including overseeing the operations and research and development of healthcare companies.

ENZON PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2009-04-13	Richard C. Mulligan, Ph.D., is the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative... The Board of Directors recommends a vote FOR Professor Mulligan as Class I Director (Proposal No. 1).
2010-06-10	Richard C. Mulligan, Ph.D. has served as a director since May 2009. Professor Mulligan is the Mallinckrodt Professor of Genetics at Harvard Medical School. The Governance and Nominating Committee currently consists of Mr. Micati (Chairman), Professor Mulligan and Messrs. Salisbury and LeBuhn. The Executive Committee consists of Dr. Denner (Chairman), Professor Mulligan and Mr. Classon.
2011-04-08	Richard C. Mulligan, Ph.D. has served as a director since May 2009 and Vice-Chairman of the Company 27s Board of Directors since March 2011. Professor Mulligan has been the Mallinckrodt Professor of Genetics at Harvard Medical School...Professor Mulligan 27s deep knowledge in the genetics field provides the Board with an important understanding...The Board has nominated and recommends that the stockholders elect Richard C. Mulligan...Vice-Chairman of the Board...Age 56...Total Director Compensation 210,012.
2012-04-06	Richard C. Mulligan has served as a director since May 2009 and Vice-Chairman of the Company 27s Board of Directors since March 2011...Professor Mulligan has been associated with a number of biotechnology companies...DIRECTOR COMPENSATION FOR FISCAL YEAR ENDED DECEMBER 31, 2011: Richard C. Mulligan Fees Earned or Paid in Cash ($) 75,750, Stock Awards ($) 131,257, Option Awards ($) 75,003, Total ($) 282,010.
2013-10-11	Dr. Denner, who has served as the Chairman of the Board since July 2009, and Professor Mulligan, who has served as the Vice-Chairman of the Board since March 2011, will not stand for re-election at the 2013 Annual Meeting. ... The Governance and Nominating Committee currently consists of Professor Mulligan (Chairman) and Dr. Denner.

Data sourced from SEC filings. Last updated: 2025-08-30